A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of YK012 in the Treatment of Moderate to Severe Systemic Lupus Erythematosus
Latest Information Update: 18 Jun 2025
At a glance
- Drugs YK 012 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Excyte Biopharma
Most Recent Events
- 15 Jun 2025 New trial record